Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US9522127B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 2013 |
| Grant date | Dec 20, 2016 |
| Priority date | — |
| Expiry date | Oct 22, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from such syndromes. The method is carried out by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl -methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 10 to 150 mg per patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.